BioSyent Releases Financial Results for Q3 and YTD 2025

About this update from Biosyent Inc.

[{"type":"text","content":"BioSyent Releases Financial Results for Q3 and YTD 2025\n\n\n\n MISSISSAUGA, Ontario, Nov. 20, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q3) and nine months (YTD) ended September 30, 2025. Key highlights include:\n \n\n\n\n (CAD)\n \n\n\n Q3 2025\n \n\n\n\n % Change vs.\n \n\n Q3 2024\n \n\n\n\n YTD 2025\n \n\n\n\n % Change vs.\n \n\n YTD 2024\n \n\n\n\n Trailing Twelve Months (TTM) Sept 30, 2025\n \n\n\n\n\n % Change vs.\n \n\n TTM Sept 30, 2024\n \n\n\n\n\n\n Canadian Pharma Sales\n \n\n\n\n 9,864,254\n \n\n\n\n +19%\n \n\n\n\n 28,351,130\n \n\n\n\n +16%\n \n\n\n\n 36,897,581\n \n\n\n\n +14%\n \n\n\n\n\n\n International Pharma Sales\n \n\n\n\n 1,153,742\n \n\n\n\n +94%\n \n\n\n\n 3,134,572\n \n\n\n\n +316%\n \n\n\n\n 3,311,306\n \n\n\n\n +310%\n \n\n\n\n\n\n Legacy Business Sales\n \n\n\n\n 1,203,808\n \n\n\n\n +83%\n \n\n\n\n 1,894,358\n \n\n\n\n +73%\n \n\n\n\n 1,967,857\n \n\n\n\n +48%\n \n\n\n\n\n\n Total Company Sales\n \n\n\n\n 12,221,804\n \n\n\n\n +28%\n \n\n\n\n 33,380,060\n \n\n\n\n +27%\n \n\n\n\n 42,176,744\n \n\n\n\n +22%\n \n\n\n\n\n\n EBITDA¹\n \n\n\n\n 3,632,399\n \n\n\n\n +27%\n \n\n\n\n 9,594,195\n \n\n\n\n +35%\n \n\n\n\n 11,835,307\n \n\n\n\n +35%\n \n\n\n\n\n\n Net Income After Taxes (NIAT)\n \n\n\n\n 2,682,340\n \n\n\n\n +16%\n \n\n\n\n 7,020,444\n \n\n\n\n +24%\n \n\n\n\n 8,633,638\n \n\n\n\n +21%\n \n\n\n\n\n\n Fully Diluted EPS\n \n\n\n\n 0.23\n \n\n\n\n +19%\n \n\n\n\n 0.61\n \n\n\n\n +28%\n \n\n\n\n 0.75\n \n\n\n\n +25%\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Return on Average Equity for TTM September 30, 2025 was 22% as compared to 20% for TTM September 30, 2024\n \n\n During YTD 2025, repurchased for cancellation a total of 19,500 common shares under a Normal Course Issuer Bid (NCIB)\n \n\n Paid quarterly cash dividends of $0.05 per common share on March 14, 2025, June 13, 2025, and September 15, 2025\n \n\n Declared subsequent cash dividend of $0.05 per common share to be paid on December 15, 2025\n \n\n\n\n\n “BioSyent delivered strong third quarter financial results,” commented Mr. René Goehrum, President and CEO of BioSyent. “Each of our three businesses performed well during the quarter, with total Company sales increasing by 28% overall. Though we experienc...

More updates from Biosyent Inc.